Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (4,394)	$ (1,336)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Amortization of intangible assets	1,436	705
Amortization of right-of-use assets	181	174
Depreciation and amortization	1,224	1,001
Amortization of deferred financing costs and debt discount	76	0
Provision for doubtful accounts	(47)	(68)
Stock-based compensation	820	1,243
Loss on disposal of property and equipment	35	63
Gain on debt extinguishment	0	(2,028)
Deferred taxes	0	8
Changes in operating assets and liabilities:
Accounts receivable	491	158
Inventories	(898)	395
Prepaid expenses and other assets	(203)	(162)
Accounts payable	1,419	(122)
Accrued expenses and other liabilities	(217)	411
Deferred revenues	(135)	128
Operating lease liabilities	(197)	(183)
Net cash (used in) provided by operating activities	(409)	387
Cash flows from investing activities:
Purchase of property and equipment	(1,510)	(1,466)
Cash paid in connection with TheraClear asset acquisition	(631)	0
Net cash used in investing activities	(2,141)	(1,466)
Net decrease in cash, cash equivalents and restricted cash	(2,550)	(1,079)
Cash, cash equivalents and restricted cash, beginning of period	12,586	18,112
Cash, cash equivalents and restricted cash, end of period	10,036	17,033
Cash and cash equivalents	10,036	9,576
Restricted cash	0	7,457
Supplemental disclosure of cash flow information:
Cash paid for interest	329	57
Supplemental disclosure of non-cash operating, investing and financing activities:
Inventories acquired in connection with TheraClear asset acquisition	71	0
Intangible assets acquired in connection with TheraClear asset acquisition	10,182	0
Contingent consideration issued in connection with TheraClear asset acquisition	9,122	0
Common stock issued in connection with TheraClear asset acquisition	500	0
Transfer of property and equipment to inventories	$ 449	$ 0